ACM
AZN icon

Advisors Capital Management’s AstraZeneca AZN Stock Holding History

Advisors Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$813K Buy
4,287
+114
+3% +$21.4K 0.01% 364
2026
Q1 		$823K Buy
4,173
+133
+3% +$25.6K 0.01% 333
2025
Q4 		$743K Buy
4,040
+271
+7% +$47.5K 0.01% 346
2025
Q3 		$578K Sell
3,769
-198
-5% -$30K 0.01% 368
2025
Q2 		$554K Sell
3,967
-114
-3% -$16K 0.01% 357
2025
Q1 		$600K Buy
4,081
+122
+3% +$17.7K 0.01% 337
2024
Q4 		$519K Sell
3,959
-710
-15% -$99.4K 0.01% 368
2024
Q3 		$728K Buy
4,669
+360
+8% +$58.1K 0.01% 325
2024
Q2 		$672K Sell
4,309
-15
-0.3% -$2.26K 0.01% 325
2024
Q1 		$586K Buy
4,324
+216
+5% +$28.6K 0.01% 341
2023
Q4 		$553K Buy
+4,108
New +$534K 0.01% 339
2023
Q3 		– Sell
-3,043
Closed -$436K – 414
2023
Q2 		$436K Buy
3,043
+66
+2% +$9.71K 0.01% 330
2023
Q1 		$413K Sell
2,977
-210
-7% -$28.3K 0.01% 326
2022
Q4 		$432K Sell
3,187
-402
-11% -$50.4K 0.01% 326
2022
Q3 		$459K Buy
+3,589
New +$455K 0.01% 327

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Advisors Capital Management's AZN Position: Q2 2026 in Review

Advisors Capital Management increased its AstraZeneca (AZN) stake by 2.7% in Q2 2026, buying an estimated $21.4K and bringing the position to 4,287 shares worth $813K. The position accounts for 0.01% of the portfolio, ranked #364.

Advisors Capital Management first reported a position in AZN in Q3 2022 and has held it in 15 quarters since. The position peaked at $823K in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Advisors Capital Management held 4,287 shares of AstraZeneca worth $813K as of Q2 2026.
  • Advisors Capital Management bought 114 AstraZeneca shares in Q2 2026, an estimated $21.4K.
  • AstraZeneca made up 0.01% of Advisors Capital Management's portfolio in Q2 2026, its #364 holding.
  • Advisors Capital Management first reported a position in AstraZeneca in Q3 2022 and has held it in 15 quarters since.
  • Advisors Capital Management's AstraZeneca position peaked at $823K in Q1 2026.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Advisors Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.